Menu
Recruiting NCT06053242

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Phase I / Phase II Interventional Chronic Low-back Pain Degenerative Disc Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CELZ-201-DDT, Placebo.
Who it may be relevant to
Registry conditions: Chronic Low-back Pain, Degenerative Disc Disease. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Double-blinded, Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Effectiveness of CELZ-201-DDT Administered by Intramuscular Injection for the Treatment of Chronic Lower Back Pain in Patients With Degenerative Disc Disease

Overview

The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.

Detailed description

This study is a double-blinded, randomized, placebo-controlled, dose escalation Phase 1/2a study. The objective is to determine the safety, tolerability, and efficacy of CELZ-201-DDT administered as an intramuscular injection for the treatment of lower back pain in patients with Degenerative Disc Disease. Subjects who meet all criteria for inclusion will be enrolled and randomized into either low, medium, high, or expanded high dose of CELZ-201-DDT versus Placebo, with a total of 45 subjects enrolled. Dosing cohorts I-III will contain ten subjects (n=10), with eight subjects (n=8) receiving the investigational product and two subjects (n=2) randomized to receive placebo. Dosing cohort IV will contain fifteen subjects (n=15), with ten subjects (n=10) receiving the investigational product and five subjects (n=5) randomized to receive placebo. Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.

Interventions

  • Drug CELZ-201-DDT
    Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
  • Other Placebo
    Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.

Primary outcome measures

  • Evaluate safety of CELZ-201-DDT administered as intramuscular injections in subjects experiencing chronic lower back pain at a low, medium, or high dose. [Time frame: 6 months]
Secondary outcome measures (3)
  • Evaluate the potential efficacy of CELZ-201-DDT therapy in terms of pain alleviation and improved mobility in subjects experiencing chronic low back pain. [Time frame: 12 months]
  • Evaluate the potential efficacy of CELZ-201-DDT therapy in terms of pain alleviation and improved mobility in subjects experiencing chronic low back pain. [Time frame: 12 months]
  • Evaluate the potential efficacy of CELZ-201-DDT therapy in terms of pain alleviation and improved mobility in subjects experiencing chronic low back pain. [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • Ability of participant to understand and the willingness to sign a written informed consent document.
  • Between 18-80 years of age and may be of either gender or any race.
  • Subjects must have failed at least two standard of care (SOC) therapies before being enrolled in the study: 1) exercise/physical therapy; 2) oral analgesic including nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; 3) skeletal muscle relaxants. Subjects must have tried each SOC therapy for at least 3 months before failure is determined.
  • Patients must have failed the SOC therapies within 12 months of enrollment in the clinical trial.
  • Proof for one of the following tests already performed in the clinical care of the patient for lower back pain: 1) MRI scan demonstrating at least one disc level with grade II or greater disc degeneration using the Pfirrmann grading system; 2) Oswestry Disability Index for Back Pain score of 21-80%; 3) Visual Analogue Scale for pain of >5 on a scale of 0-10.
  • Female subjects must not be breast feeding and must have no intention to become pregnant during the study, and she is using contraceptive drugs or devices.
  • Any male subject must agree to use contraceptives and not donate sperm during the study.
  • Subjects may be on stable opioids, narcotics, or muscle relaxants for ≥30 days before screening.

Exclusion criteria

  • History of cancer in the last five years.
  • Spinal infections and spinal tumors.
  • Renal insufficiency requiring dialysis or an eGFR of less than 60 mL/min/1.73m2.
  • ALT, AST greater than 2 times or Total Bilirubin 1.5 times the upper limit of the normal range.
  • Positive pregnancy test.
  • History of blood cell diseases.
  • Uncontrolled diabetes mellitus - HgA1c >8%.
  • Uncontrolled hypertension defined as a systolic blood pressure of >140 mmHg or diastolic blood pressure of >90 mmHg at the time of screening. If subjects have their hypertension appropriately treated, then they would be eligible to enroll.
  • Patients known to have any active infection, including infection of the injection site(s), and/or any active systemic or local infection.
  • Patients on chronic immunosuppressive transplant therapy. Patients receiving <5 mg of Prednisone daily may be included.
  • Subjects having a concomitant life-threatening disease in which their life expectancy is estimated to be less than 2 years.
  • Recent smoking history or substance abuse (within six weeks).
  • Heavy alcohol use (greater than 14 drinks per week for men or 7 drinks per week for women per NIAAA)
  • Use of an investigational drug, device or product, or participation in a drug research study within a period of 30 days prior to receiving study treatment.
  • Any patient who has received gene therapy in the past.
  • Subjects with an average baseline MED >90 mg/day during the screening period are excluded. The average will be calculated over a 7-day time period.
  • Body Mass Index (BMI) > 40 kg/m2.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Spine and Wellness Centers of America — Aventura

Identifiers

NCT: NCT06053242 · CELZ-201-ADAPT

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗